Connect with us
DAPA Banner

Crypto World

Allogene Therapeutics (ALLO) Stock Soars 41% Following Breakthrough CAR T-Cell Trial Results

Published

on

ALLO Stock Card

Key Highlights

  • ALPHA3 trial demonstrated 58.3% MRD negativity in cema-cel patients compared to just 16.7% in the observation group
  • Zero instances of cytokine release syndrome or neurotoxicity reported among treated participants
  • Baird analysts upgraded their price target from $7.00 to $9.00 while maintaining Outperform status
  • Probability of success for the therapy program increased to 70% according to Baird’s assessment
  • Shares climbed to $3.87 from $2.91, marking approximately 99% gains year-to-date

Shares of Allogene Therapeutics experienced a dramatic rally exceeding 41% on April 13, 2026, following the disclosure of encouraging interim results from the company’s crucial Phase 2 ALPHA3 clinical study examining cemacabtagene ansegedleucel (cema-cel) in patients diagnosed with high-risk large B-cell lymphoma.


ALLO Stock Card
Allogene Therapeutics, Inc., ALLO

The released information originated from an interim futility analysis conducted on the trial. Within the initial cohort of 24 randomized participants, 58.3% receiving cema-cel treatment successfully achieved minimal residual disease (MRD) negativity. By contrast, the observation group saw merely 16.7% achieve this benchmark — representing a substantial 41.6 percentage point advantage.

Researchers are utilizing Natera’s investigational CLARITY MRD assay to detect high-risk patients prior to observable clinical relapse. The study positions cema-cel as a first-line consolidation treatment option, which would represent an earlier intervention point than most existing CAR T therapeutic strategies.

Remarkable Safety Results Generate Buzz

The trial’s safety outcomes proved equally compelling as the effectiveness data. Remarkably, no treated participants developed cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome — two complications frequently linked with CAR T cellular therapies.

Additionally, zero treatment-related serious adverse events were documented. Such a clean safety profile stands out significantly within this therapeutic category, prompting Baird analysts to highlight it as a key distinguishing characteristic when evaluating cema-cel against second-line autologous CAR T alternatives.

Advertisement

The therapy’s potential for outpatient administration, coupled with these favorable safety metrics, contributes to what could be a distinctive competitive position. Current CAR T treatments typically mandate inpatient care and are associated with more substantial toxicity concerns.

Following the data announcement, Baird elevated its ALLO price objective from $7.00 to $9.00 while retaining its Outperform recommendation. The investment firm also boosted its probability of success projection for this therapeutic program to 70%.

“The limited dataset size of 12 treated patients should generate enthusiasm,” Baird wrote, acknowledging the early-stage nature of the readout while flagging the initial results as a positive signal for the commercial profile in the first-line setting.

Looking Forward

The ALPHA3 clinical study is recruiting approximately 220 participants across more than 60 clinical sites. Efficacy endpoints continue to remain blinded currently, and the available dataset remains relatively limited. These preliminary figures will require validation as additional trial data matures.

Scheduled interim event-free survival analyses are anticipated in 2027, with complete primary results projected for 2028. Favorable outcomes from these assessments could potentially support a future biologics license application submission.

Advertisement

Additional Wall Street analysts are monitoring developments closely. Jefferies recently launched coverage on ALLO with a Buy recommendation and a $6.00 price objective, while Citizens maintained its Market Outperform stance with a $5.00 target price.

ALLO shares reached $3.87 on April 13, advancing from the previous session’s close of $2.91. The equity has gained approximately 99% year-to-date and is currently trading near its 52-week peak. InvestingPro analysis indicates the stock is presently valued above its calculated fair value, though the biotechnology company maintains a balance sheet with cash holdings exceeding debt obligations.

Source link

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Crypto World

U.S. SEC says software allowing crypto wallet transactions not considered broker

Published

on

U.S. SEC says software allowing crypto wallet transactions not considered broker

The U.S. Securities and Exchange Commission said that software that sets up user interfaces allowing crypto securities to be transacted through individuals’ wallets won’t need to be registered and regulated as a broker.

In the latest of the agency’s staff statements on crypto — now a wide-ranging list of views meant to allow the crypto industry to move forward in the absence of permanent rules — the SEC staff said on Monday that the websites or software used by people pursuing securities transactions with their self-hosted wallets won’t itself be considered as belonging to the broker-dealer category. That tracks with the agency’s recent stance that developers should be able to write software without triggering such regulations.

The agency provided a checklist of measures the creators of these interfaces can take to keep them out of the regulatory box, including that it “does not solicit investors to engage in any specific crypto asset securities transactions” and “does not provide commentary on any potential execution route(s) displayed to a user.”

If the interface offers financing, provides investment recommendations, handles user assets, takes orders or executes transactions, it’s no longer outside the agency’s regulatory reach.

Advertisement

“The staff is providing its views as an interim step while the commission continues to consider various regulatory issues relating to crypto asset securities activities and the feedback it has received,” the document said.

Under the administration of President Donald Trump, who has demanded that his executive branch clear an easier path for the rise of friendly crypto regulation, the leadership of the SEC has reversed previous resistance and embraced the technology. Even before the arrival of SEC Chairman Paul Atkins, a series of pro-crypto statements began emerging, clarifying the regulator’s new view that various assets wouldn’t be considered securities or wouldn’t trigger oversight requirements. But these statements don’t carry the weight and greater permanence of full-fledged rules.

In the meantime, Atkins’ agency is working on such rules. Wide-ranging SEC rules are close to the proposal stage at the agency, he’s said. Even as the Senate continues to work on the Clarity Act that would cement crypto regulations into law, the agency is working on interim measures to give the agency great certainty.

Read More: SEC makes quiet shift to brokers’ stablecoin holdings that may pack big results

Advertisement

Source link

Continue Reading

Crypto World

Crypto-Aligned Super PAC Begins to Endorse Candidates for US Midterms

Published

on

Politics, Funding, Elections, Tether

Fellowship, a super political action committee (PAC) that claims to have $100 million in its war chest from crypto-aligned parties ahead of the 2026 US midterms, has begun reporting spending and endorsements for the next election.

According to a filing with the Federal Election Commission (FEC), the Fellowship PAC reported spending $300,000 on advertising for Clay Fuller, a Republican who won a special election for Georgia’s 14th Congressional District to replace resigning congresswoman Marjorie Taylor Greene. The spending, reported disbursed on Tuesday, comes about a month before Georgia’s Republican primary on May 19.

Politics, Funding, Elections, Tether
Source: Federal Election Commission

Fellowship is just one of several crypto-backed or aligned PACs expected to pour money to support or oppose candidates in another critical US election season. In 2024, the Fairshake PAC spent more than $130 million in media buys in congressional races, possibly influencing the outcomes in key battlegrounds like the US Senate seat for Ohio.

According to the FEC, super PACs may “receive unlimited contributions from individuals, corporations, labor unions and other PACs for the purpose of financing independent expenditures and other independent political activity.”

In addition to its only reported expenditure since the Fellowship PAC’s statement of organization filed in 2025, Fellowship posted endorsements for candidates to its X account on Thursday, signaling support for Republicans in races across five states. The candidates included Alan Wilson for South Carolina governor, Blake Miguez for Louisiana’s 5th Congressional District, Mike Collins for the US Senate in Georgia, Julia Letlow for the US Senate in Louisiana, Pete Ricketts for the US Senate in Nebraska and Nate Morris for the US Senate in Kentucky.

Advertisement

Related: Chainlink and Anchorage Digital back launch of crypto-aligned PAC

Fellowship announced its launch in September, claiming to have “over $100 million” from undisclosed backers aligned with the crypto industry. On April 1, it said that Tether’s head of government affairs, Jesse Spiro, would chair the PAC, signaling support for candidates with pro-crypto views.

US lawmakers are still stalled on crypto market structure bill as midterms approach

The CLARITY Act, legislation passed by the US House of Representatives in July, has faced several delays in the Senate with no clear path forward on passing the legislation as of Monday.

Reports over the weekend signaled that the Senate Banking Committee, one of the two bodies needed to approve the bill in the chamber before a vote, was planning to hold a markup on the legislation, but the event was not on the committee’s calendar at the time of publication.

Advertisement

The bill, expected to be one of the most comprehensive pieces of legislation affecting the crypto and banking industries, has faced pushback from lawmakers to address ethics, stablecoin yield, tokenized equities and other potential issues.

Magazine: Should users be allowed to bet on war and death in prediction markets?